Method for treating amyloidosis
Therapeutic compounds and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is inhibited by the administration to a subject of an effective amount of a therapeutic compound comprising an anionic group and a carrier molecule, or a pharmaceutically acceptable salt thereof, such that an interaction between an amyloidogenic protein and a basement membrane constituent is inhibited. Preferred anionic groups are sulfonates and sulfates. Preferred carrier molecules include carbohydrates, polymers, peptides, peptide derivatives, aliphatic groups, alicyclic groups, heterocyclic groups, aromatic groups and combinations thereof.
1 . A method for treating amyloid A amyloidosis, comprising administering to a subject an effective amount of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof.
2 . A method for treating amyloid A amyloidosis, comprising administering to a subject having amyloid A amyloidosis an effective amount of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof, such that amyloid A amyloidosis is treated.
3 . A method for treating amyloid A amyloidosis, comprising administering to a subject in need thereof an effective amount of 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof.
4 . A method for treating amyloid A amyloidosis, comprising administering to a subject in need thereof an agent such that amyloid A amyloidosis is treated in the subject by 1,3-propanedisulfonic acid or a salt thereof.
5 . A method for treating amyloid A amyloidosis, comprising administering to a subject an agent such that amyloid A amyloidosis is treated in the subject by 1,3-propanedisulfonic acid or a salt thereof.
6 . The method of claim 1 , wherein 1,3-propanedisulfonic acid sodium salt is administered to the subject.
7 . The method of claim 2 , wherein 1,3-propanedisulfonic acid sodium salt is administered to the subject.
8 . The method of claim 3 , wherein 1,3-propanedisulfonic acid sodium salt is administered to the subject.
9 . The method of claim 4 , wherein the subject is treated by 1,3-propanedisulfonic acid sodium salt.
10 . The method of claim 5 , wherein the subject is treated by 1,3-propanedisulfonic acid sodium salt.
11 . The method of any one of claims 1 - 3 and 6 - 8 , wherein the 1,3-propanedisulfonic acid or pharmaceutically acceptable salt thereof is administered to the subject in a pharmaceutical composition further comprising a pharmaceutically acceptable vehicle.
12 . The method of any one of claims 4 , 5 , 9 and 10 , wherein the agent is administered to the subject in a pharmaceutical composition further comprising a pharmaceutically acceptable vehicle.
13 . The method according to claim 11 , comprising orally administering the pharmaceutical composition.
14 . The method according to claim 12 , comprising orally administering the pharmaceutical composition.
15 . The method according to claim 13 , wherein the subject is human.
16 . The method according to claim 14 , wherein the subject is human.
17 . The method according to claim 11 , comprising intravenously administering the pharmaceutical composition.
18 . The method according to claim 12 , comprising intravenously administering the pharmaceutical composition.
19 . The method according to claim 17 , wherein the subject is human.
20 . The method according to claim 18 , wherein the subject is human.
21 . A pharmaceutical composition comprising 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof.
22 . The composition of claim 21 , wherein the pharmaceutically acceptable salt is 1,3-propanedisulfonic acid sodium salt.
23 . The composition of claim 21 , comprising 1,3-propanedisulfonic acid.
24 . The composition of claim 21 , further comprising a pharmaceutically acceptable vehicle.
25 . The composition of claim 22 , further comprising a pharmaceutically acceptable vehicle.
26 . The composition of claim 23 , further comprising a pharmaceutically acceptable vehicle.
27 . The composition according to any one of claims 21 - 26 , wherein the composition is adapted for oral administration.
28 . The composition according to any one of claims 21 - 26 , wherein the composition is adapted for intravenous administration.